Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06908928 · ClinicalTrials.gov registry record · Phase 1
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
A Phase 1 study of Triple Negative Breast Cancer, sponsored by Mabwell (Shanghai) Bioscience Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 6
- Study locations
NCT06908928 is a Phase 1 study of Triple Negative Breast Cancer that is actively recruiting participants, run by Mabwell (Shanghai) Bioscience Co.. The registered enrollment target is 52 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (79% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT06908928, a Phase 1 study of Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Mabwell (Shanghai) Bioscience Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.
Conditions Studied
Interventions
- DRUG bulumtatug fuvedotin
Study Locations (6)
California
- City of Hope - Duarte
- UCSD Moores Cancer Center - La Jolla
Colorado
- Anschutz Medical Center - Aurora
Illinois
- UChicago Medicine Comprehensive Cancer Center - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2025-08-11 |
| Est. Completion | 2028-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06908928
The ClinicalTrials.gov registry entry for NCT06908928 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (79% lower). The listed sponsor is Mabwell (Shanghai) Bioscience Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which bulumtatug fuvedotin is the first listed.
NCT06908928 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Illinois.
Frequently Asked Questions
What is clinical trial NCT06908928 about?
NCT06908928 is a clinical study titled "A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs". The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.
What is the current status of trial NCT06908928?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2025-08-11. Estimated completion is 2028-05.
What conditions does trial NCT06908928 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer.
What interventions are being tested in trial NCT06908928?
The interventions under investigation include: bulumtatug fuvedotin (DRUG).
Who is sponsoring clinical trial NCT06908928?
This trial is sponsored by Mabwell (Shanghai) Bioscience Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06908928 being conducted?
This trial has 6 study locations across California, Colorado, Illinois, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.